A Decrease in the Percentage of CD3+Cells Is Correlated With Clinical Improvement During Plasmapheresis in Patients With Myasthenia Gravis

Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis

(2011) P. J. Chien et al.   EUROPEAN JOURNAL OF NEUROLOGY

Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus

(2009) Wen-Xian Li et al.   CLINICAL RHEUMATOLOGY

Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis

(2009) J.-H. Yeh et al.   EUROPEAN JOURNAL OF NEUROLOGY

Apheresis Technologies and Clinical Applications: The 2007 International Apheresis Registry

(2009) Paul S Malchesky et al.   THERAPEUTIC APHERESIS AND DIALYSIS

CD4+T Cells and Cytokines in the Pathogenesis of Acquired Myasthenia Gravis

(2008) Bianca M. Conti-Fine et al.   Annals of the New York Academy of Sciences

Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T‐cell subsets and inflammatory cytokines

(2008) P. Szodoray et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Decrease of CD4+CD25highFoxp3+ regulatory T cells and elevation of CD19+BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis

(2007) Xiang Li et al.   CLINICAL IMMUNOLOGY